Curocell is launching its two-stage growth strategy to become a global CAR-T leader, following the approval of RIMQARTO, South Korea’s first CAR-T therapy.
Curocell’s groundbreaking CAR-T treatment RIMQARTO (RIMQARTO®·anbalcaptagen autoleucel) recently received official manufacturing and sales approval from the Korean Ministry of Food and Drug Safety under the Advanced Regenerative Medicine and Biologics Act.
This milestone makes RIMQARTO the 42nd new drug developed in South Korea, marking a significant achievement as the first successful commercialization of a CAR-T therapy by a domestic company.
RIMQARTO is gaining attention as a next-generation CD19 CAR-T therapy that incorporates Curocell’s proprietary Overcome Immune Suppression (OVIS™) technology. This innovative approach aims to combat T-cell exhaustion by regulating immune suppression signals within the tumor microenvironment, potentially extending the duration of anti-cancer activity.
The therapy has been approved for adult patients with diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) who have relapsed or are refractory after two or more systemic treatments.
Curocell sees this approval as a testament to its ability to independently establish and validate a comprehensive system for CAR-T therapies, from research and development to commercial supply. Building on this success, the company plans to accelerate global development in key markets like North America and Europe, focusing on next-generation cell and gene therapies, including solid tumors and in vivo CAR-T.
Solid Tumors, in Vivo CAR-T, and Expanding Indications
Curocell is placing a strong emphasis on solid tumor CAR-T therapies as a cornerstone of its second growth phase.
While solid tumors present significant hurdles for CAR-T therapy development due to complex factors like tumor microenvironment and antigen heterogeneity, successful treatments could revolutionize cancer care and open up substantial market opportunities.
The company aims to explore new treatment avenues for cancers with high unmet needs, such as liver, stomach, pancreatic, and colorectal cancers, leveraging next-generation platform technologies designed to enhance solid tumor treatment efficacy.
In vivo CAR-T technology is another key focus in Curocell’s long-term growth strategy. This innovative approach involves directly administering genetic material or vectors to patients, enabling CAR-T cell production within the body.
This method could streamline manufacturing processes, reduce supply timelines, and improve treatment accessibility compared to traditional ex vivo CAR-T, attracting significant interest from global pharmaceutical and biotech companies.
Curocell believes that early efficacy data from actual patients is crucial for shaping global development strategies in CAR-T therapy. The single-dose nature of CAR-T treatments allows for quicker assessment of efficacy and safety signals, enabling faster evaluation of development potential compared to conventional drugs.
Bridging Research in Asia With Global Development
To capitalize on this advantage, Curocell plans to rapidly gather efficacy data from patients in China, where investigator-initiated trials are prevalent. This data will inform their global commercialization strategy, including clinical trials, technology transfers, and potential partnerships in key markets like North America and Europe.
A Curocell spokesperson stated that by commercializing RIMQARTO in South Korea, they’re establishing a stable revenue stream while leveraging the research in Asia to drive the expansion into advanced markets. The goal is to evolve from South Korea’s first CAR-T developer into a global leader in cell and gene therapy.
Following RIMQARTO’s domestic approval, Curocell is pursuing entry into the Japanese market and expanding indications for second-line treatments. The company is also advancing its research and development (R&D) efforts in autoimmune diseases and solid tumors.
Curocell’s strategy involves simultaneously expanding RIMQARTO’s indications and global reach while developing next-generation therapies. The company aims to demonstrate the versatility of its CAR-T platform by extending applications to solid tumors and autoimmune diseases.